Bethesda, Maryland 20892

  • Radiation Fibrosis


RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in patients who have undergone radiation therapy for cancer.

Study summary:

OBJECTIVES: - Determine the safety and therapeutic efficacy of pirfenidone in cancer patients with radiation-induced fibrosis. OUTLINE: Patients receive oral pirfenidone 3 times daily. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Principal functional abilities are assessed at baseline, every 3 months, and at termination of therapy. PROJECTED ACCRUAL: A total of 10-25 patients will be accrued for this study within 1 year.


DISEASE CHARACTERISTICS: - Regional post-radiation fibrosis of a specific body area (e.g., neck, back, or extremities) - At least moderate impairment in at least 1 of the following principal functional abilities: - Range of motion - Strength - Edema - Swallowing - Prior radiation for cancer received more than 6 months ago - No evidence of recurrent or metastatic cancer - No history of collagen vascular disease - No positive antinuclear antibody PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Hepatitis B and C negative Renal: - Not specified Other: - HIV negative - No evidence of second primary cancer - No life-threatening situation requiring rehabilitation intervention - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent anticancer immunotherapy Chemotherapy: - No concurrent anticancer chemotherapy Endocrine therapy: - No concurrent anticancer hormonal therapy Radiotherapy: - See Disease Characteristics - No concurrent anticancer radiotherapy Surgery: - Not specified Other: - No other concurrent anticancer investigational agents - Stable doses of medicine (e.g., non-steroidal anti-inflammatory drugs) currently being taken are allowed



Primary Contact:

Principal Investigator
Kevin Camphausen, MD
NCI - Radiation Oncology Branch; ROB

Backup Contact:


Location Contact:

Bethesda, Maryland 20892
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.